<DOC>
	<DOCNO>NCT01812980</DOCNO>
	<brief_summary>The overall aim project evaluate immunogenicity TIV vaccination HIV-infected non-pregnant woman 2013 . Safety data include solicit local systemic reaction vaccine also assess .</brief_summary>
	<brief_title>Immunogenicity Safety Trivalent Influenza Vaccine Non-pregnant HIV-infected Women</brief_title>
	<detailed_description>Schedule Events Visit 1 ( enrollment ) Informed Consent Form ( ICF ) sign Inclusion/ exclusion/ Withdrawal criterion Medical history Targeted physical exam Blood draw TIV administer Diary card dispense Local/ systematic reaction Visit 2 : 1 month post enrolment ( 28-35 day ) Inclusion/ exclusion/ Withdrawal criterion Medical history Targeted physical exam Blood draw Diary card collect Local/ systematic reaction review</detailed_description>
	<mesh_term>Influenza , Human</mesh_term>
	<mesh_term>Immunologic Deficiency Syndromes</mesh_term>
	<mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>( ) Documented HIV1 infect one assay use Prevention Mother Child Transmission ( PMTCT ) / program undertaken within 12 week study enrolment . Able understand comply plan study procedure . Provides write informed consent prior initiation study . Not pregnant time enrolment ( confirm urine test ) . If pregnant past year , participant must least 6 month post delivery time enrolment . Women age ≥ 18 year &lt; 39 year . Receipt TIV , study , current previous two influenza season , document medical history record . Receipt live license vaccine ≤ 28 day vaccine ( except tetanus toxoid vaccine ) ≤ 14 day prior studyvaccine . Receipt nonlicensed agent ( vaccine , drug , biologic , device , blood product , medication ) ≤ 28 day prior vaccination study , unless study approval obtain . Any significant ( opinion site investigator ) acute illness and/or oral temperature great equal 38 degree C ≤ 24 hour prior study entry . Use anticancer systemic chemotherapy radiation therapy ≤ 48 week study enrollment , immunosuppression result underlie illness treatment . Long term use glucocorticoid , include oral parenteral prednisone ≥ 20 mg/day equivalent 2 consecutive week ( 2 week total ) ≤ 12 week study entry , highdose inhaled steroid ( &gt; 800 mcg/day beclomethasone dipropionate equivalent ) ≤ 12 week study entry ( nasal topical steroid allow ) . Receipt immunoglobulin blood product ( exception Rho D immune globulin ) ≤ 12 week prior enrollment study schedule receive immunoglobulin blood product . Receipt Interleukin 2 , IFN , GMCSF immune mediator ≤ 12 week enrollment . Uncontrolled major psychiatric disorder . History severe adverse reaction previous TIV . Any condition would , opinion site investigator , place subject unacceptable risk injury render subject unable meet requirement protocol .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>39 Years</maximum_age>
	<verification_date>December 2013</verification_date>
	<keyword>Influenza</keyword>
	<keyword>Human Immunodeficiency Virus</keyword>
</DOC>